Last $19.32 USD
Change Today +0.07 / 0.36%
Volume 454.6K
LMNX On Other Exchanges
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/14 - $21.69
52 Week Low
04/28/14 - $15.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The company operates in two segments: Technology and Strategic Partnerships (TSP); and Assays and Related Products (ARP). The TSP segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a versatile multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The ARP segment develops and sells assays on xMAP, xTAG, and MultiCode technology for use on its installed base of systems. It provides various assay products that consist of a combination of chemical and biological reagents; and company’s proprietary bead technology used to perform diagnostic and research assays on samples. This segment’s products are focused on the human genetics, personalized medicine, and infectious disease segments of the molecular diagnostic testing market. Luminex Corporation serves pharmaceutical companies, clinical laboratories, and research and medical institutions in the United States, Europe, Asia, Canada, Australia, and internationally. The company has collaboration with Merck & Co. Inc. to develop a companion diagnostic device. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

731 Employees
Last Reported Date: 02/26/14
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $320.9K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $319.2K
Total Annual Compensation: $700.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $345.6K
Compensation as of Fiscal Year 2013.

luminex corp (LMNX) Key Developments

Luminex Corporation Announces Management Changes

Luminex Corporation announced that Patrick J. Balthrop, Sr. has retired as President and CEO. The board of directors has named Nachum 'Homi' Shamir as President and CEO. Mr. Balthrop has resigned as a director but will continue to serve the company and its shareholders as a consultant to the Board and Mr. Shamir, and will be assisting in the transition through April 14, 2015. Mr. Shamir is expected to be invited to join the board of directors. Mr. Shamir most recently served as President and Chief Executive Officer at Given Imaging from 2006 until February 2014.

Luminex Corporation Receives FDA Clearance to Add New Clinical Targets and Additional Sample Type for Use With xTAG Gastrointestinal Pathogen Panel

Luminex Corporation announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel. The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. In addition, FDA has now cleared xTAG GPP for use with specimens in Cary-Blair medium, a common transport medium for collection and preservation of microbiological specimens. As the first multiplexed U.S. IVD cleared test for infectious gastroenteritis, xTAG GPP simultaneously detects 14 common viral, bacterial, and parasitic causative pathogens from a single patient sample. By testing for greater than 90% of the causative pathogens of infectious gastroenteritis in a single test, clinicians can more quickly identify and treat the causative agent. Additionally co-infections can be more easily identified. Simultaneous molecular testing on a single sample within a single shift also provides significant benefits to laboratories in terms of workflow and resource utilization. The ability to scale throughput by processing 96-well plates allows laboratories to easily tailor their sample processing to physician demand.

Luminex Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:10 AM

Luminex Corporation Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:10 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Patrick J. Balthrop, Chief Executive Officer, President, Director, Member of Executive Committee and Member of Strategy & Development Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $19.32 USD +0.07

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $59.80 USD -0.47
Fluidigm Corp $25.60 USD -0.80
HealthStream Inc $24.29 USD -0.46
Meridian Bioscience Inc $17.54 USD -0.12
Quidel Corp $28.43 USD +0.97
View Industry Companies

Industry Analysis


Industry Average

Valuation LMNX Industry Range
Price/Earnings 49.0x
Price/Sales 3.7x
Price/Book 2.8x
Price/Cash Flow 40.0x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at